Silence Therapeutics completes SANRECO Phase 2 enrollment for divesiran in PV; topline data expected 3Q'26

Silence Therapeutics plc

48 phlebotomy-dependent PV patients enrolled in global, randomized, double-blind, placebo-controlled study.
Primary endpoint: proportion maintaining HCT <45% without phlebotomies between weeks 18 and 36.
Phase 2 evaluates two dosing intervals (Q6W and Q12W); Phase 1 showed potential with Q6W dosing.
Topline results anticipated in the third quarter of 2026.
CEO cites divesiran as first-in-class siRNA targeting TMPRSS6 for significant unmet need in PV.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.